2024年11月27日 · What causes PIRA, or progression independent of relapse activity? Learn more about smoldering MS and new research on neurodegeneration and PIRA treatments.

2024年6月18日 · Progression independent of relapse activity (PIRA), a recent concept to formalize disability accrual in multiple sclerosis (MS) independent of relapses, has gained popularity as a potential clinical trial outcome. We discuss its shortcomings and appraise ...

2023年4月6日 · A signal of progression, with or without relapses, in advanced MS has been recognised for many years and constitutes the phenotype of Secondary Progressive MS (SPMS). The novel dimension of PIRA, as it relates to this review, is that it is …

A new term in MS research that has emerged in recent years is PIRA, or progression independent of relapse activity. It purports to quantify the proportion of disability worsening due to non-inflammatory neurodegenerative processes.

2024年5月15日 · Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple...

2023年6月23日 · Detailed exploration of studies evaluating the use of highly effective treatments have unveiled the clinical concept of progression independent of disease activity (PIRA), or an accumulation of disability in the absence of relapse-associated worsening (RAW), in …

Discover how addressing progression independent of relapse activity (PIRA) remains a significant unmet need in people with multiple sclerosis (MS).

Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA regarded as a feature of primary and secondary progressive multiple sclerosis.

Most people with MS are diagnosed with relapsing-remitting MS, but those with this type of MS can still experience silent progression without relapses.

The currently available research supports the presence of PIRA in relapsing MS. Based on review of the existing literature, we propose a definition of PIRA that is clinically relevant and minimises confounding from inclusion of patients who have reached the secondary progressive phase of …